scholarly journals Effectiveness of Kinesiotaping in Pregnant Women with Sacroiliac Joint Pain: A Randomized Controlled Study

2021 ◽  
Author(s):  
banu ordahan ◽  
Jule Eriç Horasanlı
Keyword(s):  
Quality Of Life ◽  
Pregnant Women ◽  
Sacroiliac Joint ◽  
Joint Pain ◽  
Treatment Options ◽  
Controlled Study ◽  
Sacroiliac Joint Pain ◽  
Gestational Week ◽  
Disability Questionnaire

Aim Sacroiliac joint dysfunction is an especially common cause of pain during pregnancy. Treatment options during pregnancy are very limited in order to reduce pain and increase the quality of life. We aimed to determine the efficacy of kinesiotaping (KT) in the treatment of sacroiliac joint pain in pregnant women. Methods A total of 50 pregnant women with sacroiliac joint pain were included in the study. Patients were randomized into two groups as KT and sham KT groups. Women in the KT group underwent a total of five weeks of KT once per week; the sham KT group also underwent five weeks of KT applications, but without tension in the kinesiotape. Patients were assessed before and five weeks after the treatment with a visual analogue scale (VAS) for pain and the Roland-Morris Disability Questionnaire (RMDQ) and Pelvic Girdle Questionnaire (PGQ) for disability and quality of life. Results The KT and sham KT groups were similar in terms of age, parity, gravidas, gestational week, and body mass index. At the beginning of the study, there were no statistically significant differences between the two groups in their VAS, RMDQ, or PGQ scores. Five weeks later, the KT group showed significant improvement in all parameters, but no significant differences were observed for the sham KT group in terms of VAS, RMDQ, or PGQ. Conclusions KT treatment improved the pain levels, functioning, and quality of life among pregnant women with sacroiliac joint pain. Keywords Sacroiliac joint pain; Pregnancy; Kinesiotaping

scholarly journals Randomized Placebo-controlled Study Evaluating Lateral Branch Radiofrequency Denervation for Sacroiliac Joint Pain

2008 ◽  
Vol 109 (2) ◽  
pp. 279-288 ◽  
Author(s):  
Steven P. Cohen ◽  
Robert W. Hurley ◽  
Chester C. Buckenmaier ◽  
Connie Kurihara ◽  
Benny Morlando ◽  
...  
Keyword(s):  
Pain Relief ◽  
Local Anesthetic ◽  
Sacroiliac Joint ◽  
Joint Pain ◽  
Lateral Branch ◽  
Controlled Study ◽  
Sacroiliac Joint Pain ◽  
Long Term Treatment ◽  
Radiofrequency Denervation ◽  
Dorsal Rami

Background Sacroiliac joint pain is a challenging condition accounting for approximately 20% of cases of chronic low back pain. Currently, there are no effective long-term treatment options for sacroiliac joint pain. Methods A randomized placebo-controlled study was conducted in 28 patients with injection-diagnosed sacroiliac joint pain. Fourteen patients received L4-L5 primary dorsal rami and S1-S3 lateral branch radiofrequency denervation using cooling-probe technology after a local anesthetic block, and 14 patients received the local anesthetic block followed by placebo denervation. Patients who did not respond to placebo injections crossed over and were treated with radiofrequency denervation using conventional technology. Results One, 3, and 6 months after the procedure, 11 (79%), 9 (64%), and 8 (57%) radiofrequency-treated patients experienced pain relief of 50% or greater and significant functional improvement. In contrast, only 2 patients (14%) in the placebo group experienced significant improvement at their 1-month follow-up, and none experienced benefit 3 months after the procedure. In the crossover group (n = 11), 7 (64%), 6 (55%), and 4 (36%) experienced improvement 1, 3, and 6 months after the procedure. One year after treatment, only 2 patients (14%) in the treatment group continued to demonstrate persistent pain relief. Conclusions These results provide preliminary evidence that L4 and L5 primary dorsal rami and S1-S3 lateral branch radiofrequency denervation may provide intermediate-term pain relief and functional benefit in selected patients with suspected sacroiliac joint pain. Larger studies are needed to confirm these results and to determine the optimal candidates and treatment parameters for this poorly understood disorder.

scholarly journals Nonoperative Treatment Options for Patients With Sacroiliac Joint Pain

10.14444/6082 ◽  
2020 ◽  
Vol 14 (s1) ◽  
pp. S35-S40 ◽  
Author(s):  
Heidi Prather ◽  
Michael Bonnette ◽  
Devyani Hunt
Keyword(s):  
Sacroiliac Joint ◽  
Joint Pain ◽  
Treatment Options ◽  
Nonoperative Treatment ◽  
Sacroiliac Joint Pain

scholarly journals Chronic sacroiliac joint pain: fusion versus denervation as treatment options

2010 ◽  
Vol 1 (03) ◽  
pp. 35-44 ◽  
Author(s):  
Bryan Ashman ◽  
Daniel Norvell ◽  
Jeffrey Hermsmeyer
Keyword(s):  
Sacroiliac Joint ◽  
Joint Pain ◽  
Treatment Options ◽  
Sacroiliac Joint Pain

Raynaud’s phenomenon and digital ischaemia - pharmacologic approach and alternative treatment options

VASA ◽  
2016 ◽  
Vol 45 (3) ◽  
pp. 201-212 ◽  
Author(s):  
Birgit Linnemann ◽  
Matthias Erbe
Keyword(s):  
Quality Of Life ◽  
Angiotensin Receptor Blockers ◽  
Raynaud’S Phenomenon ◽  
Treatment Options ◽  
Raynaud's Phenomenon ◽  
Tissue Loss ◽  
Receptor Antagonists ◽  
Skin Ulcers ◽  
Digital Ischaemia

Abstract. The primary goal of therapy is to reduce the frequency and intensity of Raynaud’s attacks and to minimize the related morbidity rather than to cure the underlying condition. Treatment strategies depend on whether Raynaud’s phenomenon (RP) is primary or secondary. All patients should be instructed about general measures to maintain body warmth and to avoid triggers of RP attacks. Pharmacologic intervention can be useful for patients with severe and frequent RP episodes that impair the patient’s quality of life. Calcium channel blockers are currently the most prescribed and studied medications for this purpose. There has been limited evidence for the efficacy of alpha-1-adrenergic receptor antagonists, angiotensin receptor blockers, topical nitrates or fluoxetine to treat RP. The intravenously administered prostacyclin analogue iloprost can reduce the frequency and severity of RP attacks and is considered a second-line therapy in patients with markedly impaired quality of life, critical digital ischaemia and skin ulcers who are at risk for substantial tissue loss and amputation. Phosphodiesterase inhibitors (e.g., sildenafil) can also improve RP symptoms and ulcer healing whereas endothelin-1 receptor antagonists (e.g., bosentan) are mainly considered treatment options in secondary prevention for patients with digital skin ulcers related to systemic sclerosis. However, their use in clinical practice has been limited by their high cost. Antiplatelet therapy with low-dose aspirin is recommended for all patients who suffer from secondary RP due to ischaemia caused by structural vessel damage. Anticoagulant therapy can be considered during the acute phase of digital ischaemia in patients with suspected vascular occlusive disease attributed to the occurrence of new thromboses. In patients with critical digital ischaemia, consideration should be given to hospitalisation, optimisation of medical treatment in accordance with the underlying disease and evaluation for a secondary, possibly reversible process that is causing or aggravating the clinical symptoms.

Sign in / Sign up

Export Citation Format

Share Document